Curetis develops and commercializes the Unyvero molecular diagnostic platform that delivers rapid multi-parameter pathogen and antibiotic-resistance marker detection in only a few hours. The company intends to further develop and validate complementary technology assets and associated IP, fund clinical trials, and integrate the recently acquired GEAR database and assets into its platform. The financing is targeted to accelerate R&D activities and to broaden the pipeline of applications for Unyvero. Founded in 2007 and based in Holzgerlingen near Stuttgart, Germany, Curetis focuses on fast, cost-effective diagnostics for severe infectious diseases. To date the company has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Brussels and over EUR 63.5 million in private equity, and it has now entered into an EIB debt facility up to EUR 25 million. The funding is expected to cover up to 50% of Curetis’s expected medium-term R&D project requirements, including R&D staff costs, external R&D operating expenses and related capital expenditures. Curetis is a German developer of next-generation molecular diagnostics centered on its Unyvero platform. The Unyvero system is a comprehensive diagnostics platform for severe infectious diseases in hospitalized patients, using a variety of cartridges to diagnose conditions such as pneumonia and implant and tissue infections within four to five hours. The Unyvero P50 Pneumonia and i60 Implant and Tissue Infection applications are already approved for use in Europe. Curetis will use the new funds to support the European product rollout and to run a U.S. clinical trial of Unyvero; the company is also looking to bring its tests to Asian markets. Management said it is pursuing attractive future exit opportunities including strategic partnerships, M&A or an IPO. The new financing increases the company’s total equity raised to more than $79.2 million and, according to the company, finances operations well into 2017. Curetis AG announced the closing of a Series B financing totaling EUR 12.5 million. The round was led by HBM Partners, which took an EUR 6.0 million equity stake in Curetis. Dr. Alexander Asam of HBM Partners will join Curetis' supervisory board. The announcement was presented as portfolio news. No other investors or financing instruments were disclosed in the article. No operating metrics, past rounds, founding year, or location were provided. Curetis, founded in 2007 and based in Holzgerlingen near Stuttgart, Germany, develops and commercializes rapid molecular diagnostic solutions. Its core product, the Unyvero System, is designed to detect pathogens and antibiotic resistance markers within a few hours. The technology aims to enable clinicians to diagnose causes of severe infections faster and begin targeted antibiotic regimens immediately for critically ill patients. The company is led by CEO Oliver Schacht, PhD, with CTO Andreas Boos and COO Johannes Bacher. Curetis has been advancing commercialization alongside continued development of its diagnostic platform. Recent financing activity has supported its near-term growth and Board expansion. Curetis AG develops and commercializes in vitro diagnostic products for infectious diseases, centered on its Unyvero product platform. The company intends to use newly raised funds to prepare for commercial launch and roll-out of Unyvero together with a CE‑marked IVD test cartridge for pneumonia and antibiotic resistances. Unyvero is a hardware platform designed to detect a broad panel of bacteria and antibiotic resistances from a single sample in one run. Curetis is based in Holzgerlingen, Germany, and recently appointed Oliver Schacht, PhD, as CEO. Financially, the company has been capitalizing its commercialization push through equity financing, including a prior €18.5m raise in 2009.

Total raised

$110M

Funding rounds

6

Latest round

Debt Financing

Latest activity

Dec 2016